Simon Couillard

Prix et distinctions

• (2021) Distinction - MSc in Experimental and Translational Therapeutics. University of Oxford University College Oxford.
• (2021) BTS Winter Meeting Conference Grant. British Thoracic Society.
• (2021) Abstract scholarship: proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE). American Thoracic Society.
• (2018) Abstract scholarship: Miliary pneumonia as a novel radiological manifestation of Q fever. American Thoracic Society.

Financement

• Subvention. The Canadian Lung Outcomes in Users of Vaping Devices (CLOUD) Study. Canadian Institutes of Health Research (Ottawa, Canada). 799 781 $. (2024-2029).
  Numéro de subvention : 202311LG1. Voir plus
• Subvention. Canadian consortium for understanding the role of airway mucus occlusions in cough, COPD and asthma (CANMuc). Canadian Institutes of Health Research (Ottawa, Canada). 2 000 000 $. (2024-2029).
  Numéro de subvention : 202311LG8. Voir plus
• Subvention. Blood Eosinophils and Fractional Exhaled Nitric Oxide for Prediction of Asthma Attacks: Patient-Level Meta-Analysis and Risk Modelling. Academy of Medical Sciences (London, Royaume-Uni). 25 000 GBP. (2024-2025).
  Numéro de subvention : NGR1\1937. Voir plus
• Subvention. Programme de recherche clinique et translationnel pour la prédiction, prévention, et prise en charge personnalisée de l'asthme. Fonds de Recherche du Québec - Santé (Montreal, Canada). 123 415 $. (2023-2027).
  Numéro de subvention : 331512. Voir plus
• Subvention. Programme de recherche clinique et translationnel pour la prédiction, prévention, et prise en charge personnalisée de l'asthme. Fonds de Recherche du Québec - Santé (Montreal, Canada). 15 000 $. (2023-2024).
  Numéro de subvention : 339756. Voir plus
• Subvention. Phenotyping Responses to Systemic Corticosteroids in the Management Asthma Attacks (PRISMA): microbiomic substudy. bioMérieux (Lyon, France). 90 000 USD. (2023-2025).
• Subvention. Diagnostic and translational values of point-of-care blood eosinophils and exhaled nitric oxide (FeNO) in people referred by primary care for suspected asthma: a pilot study. AstraZeneca (Canada) (Mississauga, Canada). 152 000 $. (2023-2025).
• Subvention. Diagnostic and translational values of point-of-care blood eosinophils and exhaled nitric oxide (FeNO) in people referred by primary care for suspected asthma: a pilot study. Fondation Québécoise en Santé Respiratoire (Montréal, Canada). 40 000 $. (2023-2024).
• Subvention. Phenotyping Responses to Systemic Corticosteroids in the Management Asthma Attacks (PRISMA): Clinical and Translational Correlation to Type-2 Inflammatory Biomarkers. Sanofi (United States) (Bridgewater, États-Unis). Pathways Global Innovation Grant. 205 000 $. (2022-2024).
• Subvention. Association Pulmonaire du Québec research chair for respiratory health. Association Pulmonaire du Québec (Montréal, Canada). Research Chair. 388 800 $. (2022-2027).
• Subvention. Towards the personalised prediction, prevention, and management of asthma attacks (PRISMA): setup of a collaborative translational phenotyping asthma attack service in Sherbrooke. Quebec Respiratory Health Research Network (Montreal, Canada). Career Start-Up & Mentorship Program for Young Investigators. 25 000 $. (2022-2023).
• Subvention. Type 2 Innovation Grant- Mechanisms of FeNO non-suppression. Sanofi Genzyme (MA, Royaume-Uni). Innovation. 80 000 EUR. (2019-2021).
• Subvention salariée. Severe asthma clinical fellowship / MSc at the University of Oxford. Société des Médecins de l'Université de Sherbrooke (Sherbrooke, Canada). Fellowship. 150 000 $. (2019-2021).

Publications

Articles

• Joël St-Pierre, Simon Couillard. (2025). Biomarker Suppression in Asthma: How Low Can You Go?. The Journal of Allergy and Clinical Immunology: In Practice. DOI
• Simon Couillard, Samuel Mailhot-Larouche, Fleur L. Meulmeester, Guy Brusselle, Philippe Lachapelle, Richard W. Beasley, Jacob K. Sont, Ewout W. Steyerberg, Ian D. Pavord, Njira Lugogo. (2025). Normal FEV1 without Reversibility in Asthma Trials: A Placebo Patient-Level Meta-Analysis. American Journal of Respiratory and Critical Care Medicine. DOI
• Carlos Andres Celis-Preciado, Elsa Ben Hamou Kuijpers, Sanjay Ramakrishnan, Imran Howell, Michael E. Wechsler, Praveen Akuthota, Simon Couillard. (2025). Applying Precision Medicine to the Heterogeneity of Asthma Attacks. CHEST. DOI
• James Melhorn, Simon Couillard. (2025). Baseline Membrane Thickness in Asthma: Where Type-2 Inflammation Meets Remodeling?. American Journal of Respiratory and Critical Care Medicine. DOI
• Elsa Ben Hamou-Kuijpers, Simon Couillard. (2025). Smoking gun: when COPD therapies fail current smokers. Thorax. DOI
• Samuel Mailhot-Larouche, Philippe Lachapelle, Simon Couillard. (2025). What Sex-Specific Differences Tells Us About Additive vs Synergistic Risk Prediction in Asthma. CHEST Pulmonary. DOI
• Simon Couillard, Sanjay Ramakrishnan. (2025). In the Land of Asthma, 4 Risk Factors to Rule Them All. CHEST. DOI
• Sandrine Massé, Joël St-Pierre, Tommy Delisle, Félix-Antoine Vézina, Christian Iorio-Morin, Simon Couillard. (2025). Neuromodulation of dyspnea – A literature review. Respiratory Medicine. DOI
• Joël St-Pierre, Samuel Mailhot-Larouche, Geneviève Garand, Félix-Antoine Vézina, Guillaume Léonard, Christian Iorio-Morin, Simon Couillard. (2025). Non-invasive neuromodulation for alleviating dyspnoea: protocol for a feasibility sham-controlled randomised trial. BMJ Open. DOI
• Carlos Celis-Preciado, Samuel Lemaire-Paquette, Philippe Lachapelle, Simon Couillard. (2025). Reply to: Type 2 inflammatory biomarkers in asthma and COPD: what we think we know. European Respiratory Journal. DOI
• Simon Couillard, David J. Jackson, Ian D. Pavord, Michael E. Wechsler. (2025). Response. CHEST. DOI
• Mohamed-Ilias Kourid, Simon Couillard. (2025). Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?. European Respiratory Journal. DOI
• Simon Couillard, Dominic L. Sykes, Mustafa Abdo, Freda Yang, Sanjay Ramakrishnan, James D. Chalmers, Christina S. Thornton. (2025). Viewpoint: a white paper for a greener design, conduct and reporting of clinical trials in respiratory medicine. European Respiratory Journal. DOI
• Paloma Burns, Rachel L Eddy, Xuan Li, Julia Yang, Satvir S Dhillon, Simon Couillard, Michael K Stickland, Jordan Guenette, Sarah Svenningsen, Trisha Tulloch, Hasina Samji, Rafael Meza, Laura L Struik, Shawn Aaron, Terence Ho, Stephen Lam, Jonathon Leipsic, Joanna Maclean, Tina Afshar, ... Janice M Leung. (2025). The Canadian Lung Outcomes in Users of Vaping Devices (CLOUD) Study: protocol for a prospective, observational cohort study. BMJ Open. DOI
• Simon Couillard, David J. Jackson, Ian D. Pavord, Michael E. Wechsler. (2025). Choosing the Right Biologic for the Right Patient With Severe Asthma. CHEST. DOI
• Samuel Mailhot-Larouche, John Busby, Simon Couillard. (2025). Response and remission in asthma with tezepelumab: overlapping concepts informing on type-2 inflammatory-dependent treatment effects. European Respiratory Journal. DOI
• Samuel Mailhot-Larouche, Carlos Celis-Preciado, Liam G. Heaney, Simon Couillard. (2025). Identifying super-responders. Annals of Allergy, Asthma & Immunology. DOI
• Lauranne Pouliot, Laurence Désy, Sarah-Ève Lemieux, Carlos Andrés Celis-Preciado, Samuel Lemaire-Paquette, Martine Duval, Simon Leclerc, Félix-Antoine Vézina, Philippe Lachapelle, Simon Couillard. (2025). The carbon footprint of diagnostic delays in asthma. ERJ Open Research. DOI
• (2025). BASELINE CHARACTERISTICS ASSOCIATED WITH MULTICOMPONENT CLINICAL REMISSION FOLLOWING DUPILUMAB TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE ASTHMA. INTERNAL MEDICINE JOURNAL.
• Schleich, F., Larenas-Linnemann, D., Altraja, A., Pérez de Llano, L., Kostikas, K., Sadatsafavi, M., Bourdin, A., Alton Pleasants, R., Hew, M., Chen, W., Jiménez-Maldonado, L., Couillard, S., Suppli Ulrik, C., Bulkhi, A.A., Tsai, M.-J., Christoff, G.C., Papadopoulos, N.G., Pfeffer, P.E., Ryan, D., ... Price, D.B. (2025). Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR). World Allergy Organization Journal. DOI
• (2025). Biomarkers Poorly Distinguish Nasal Polyposis History in Patients Participating in Asthma Clinical Trials: Findings From the ORACLE2 Patient-level Meta-analysis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• Pott, H., Sykes, D.L., Charriot, J., Finney, L., Yang, F., Ramakrishnan, S., Abdo, M., Couillard, S. (2025). Breathing barriers: bridging lung health, research, and awareness. Lancet Respiratory Medicine. DOI
• (2025). Fractional Exhaled Nitric Oxide and Asthma Control in Moderate to Severe Asthma Patients Treated With Omalizumab: A Retrospective Cohort Study. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• Cantin, A.M., Couillard, S., Praud, J.-P. (2025). History of respiratory medicine in Sherbrooke, Quebec. Canadian Journal of Respiratory Critical Care and Sleep Medicine. DOI
• Chen, W., Tran, T.N., Townend, J., Christoff, G.C., Tsai, M.-J., Altraja, A., Cochrane, B., Cosio, B.G., Sivori, M., Murray, R.B., Makris, M.P., Scelo, G., Bulathsinhala, L., Ardusso, L.R.F., Franchi, M.E., Máspero, J., Saldarini, F., Stok, A.M., Tomaszuk, A.G., ... Price, D.B. (2025). Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data. Journal of Allergy and Clinical Immunology in Practice. DOI
• (2025). Impact of Dupilumab on Type 2 Inflammatory Biomarkers in Patients With Chronic Obstructive Pulmonary Disease (COPD). AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• Meulmeester, F.L., Mailhot-Larouche, S., Celis-Preciado, C., Lemaire-Paquette, S., Ramakrishnan, S., Wechsler, M.E., Brusselle, G., Corren, J., Hardy, J., Diver, S.E., Brightling, C.E., Castro, M., Hanania, N.A., Jackson, D.J., Martin, N., Laugerud, A., Santoro, E., Compton, C., Hardin, M.E., ... Couillard, S. (2025). Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respiratory Medicine. DOI
• Gronnier, M., Désy, L., Pouliot, L., Lemieux, S.-È., Vézina, F.-A., Lachapelle, P., Counil, F.-P., Duval, M., Cliche, D., Lemaire-Paquette, S., Coulibaly, L., Hudon, C., Lands, L.C., Ducharme, F.M., Tse, S., Couillard, S. (2025). Integrating blood eosinophils and exhaled nitric oxide (FeNO) in asthma diagnostic pathways for adults and children: the PROPULSION SANTÉ observational study with translational sub-studies (DIVE, DIVE2)—protocols. BMJ Open Respiratory Research. DOI
• (2025). Non-tuberculous Mycobacteria in Patients With Severe Eosinophilic Asthma Under Biological Treatment. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• Celis-Preciado, C., Leclerc, S., Duval, M., Cliche, D.O., Brazeau, L., Vézina, F.-A., Dussault, M., Larivée, P., Lemaire-Paquette, S., Lévesque, S., Lachapelle, P., Couillard, S. (2025). Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA). European Respiratory Journal. DOI
• Sadatsafavi, M., Tran, T.N., Scelo, G., Tsai, M.-J., Busby, J., Emmanuel, B., Heaney, L.G., Jenkins, C., Hoyte, F., Canonica, G.W., Katial, R., Heffler, E., Wang, E., Puggioni, F., Wechsler, M.E., Ardusso, L.R.F., Máspero, J., Sivori, M., Emmas, C., ... Price, D.B. (2025). Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics. American Journal of Respiratory and Critical Care Medicine. DOI
• (2025). Prognostic Interaction Between Inflammatory and Clinical Risk Factors for Asthma Attacks: Findings From the ORACLE2 Patient-level Meta-analysis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• St-Germain, O., Phan, F., Celis-Preciado, C., Beaudoin-Grondin, B., Poulin, Y., Vézina, F.-A., Garand, G., Lemaire-Paquette, S., Malick, M., Larivée, P., Lachapelle, P., Couillard, S. (2025). Real-life efficacy of type-2 targeting biologicals in the withdrawal from oral corticosteroid maintenance therapy in severe asthma: A retrospective cohort study. Canadian Journal of Respiratory Critical Care and Sleep Medicine. DOI
• (2025). Reduction of Exacerbations According to Type 2 Inflammatory Biomarkers With Dupilumab Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD). AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• (2025). Type 2 Inflammatory Biomarkers and Lung Function Improvement in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Placebo Therapy. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• Pavord, I.D., Lavoie, G., Couillard, S. (2025). Type 2 biomarkers and assessment of risk. Ers Monograph. DOI
• (2025). Type-2 Inflammation and Lung Function Changes in the Placebo Arms of Asthma Clinical Trials: Findings From the ORACLE2 Meta-analysis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• Di Flumeri, E., Ducharme, F.M., St-Pierre, J., Niazi, F., Shlobin, N.A., Couillard, S., Praud, J.-P., Weil, A.G., Iorio-Morin, C. (2025). Vagus nerve stimulation as a potential treatment for acute asthmatic bronchoconstriction: a systematic review. Frontiers in Physiology. DOI
• (2025). Win Ratio Analysis of BOREAS and NOTUS: Faster Trials, Clearer Wins for Patients With Chronic Obstructive Pulmonary Disease With Type 2 Inflammation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. DOI
• Couillard, S., Pavord, I., Hoyte, F., Siddiqui, S., Martin, N., Menzies-Gow, A., Lommatzsch, M. (2025). ”Treat-to-Target”: A Call for Earlier Targeted Intervention in Asthma. Journal of Allergy and Clinical Immunology in Practice. DOI
• Mathieu D. Saint-Pierre, Simon Couillard. (2024). Acute chronic obstructive pulmonary disease (COPD) presentations with and without pneumonia: To lump or split, that is the question. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. DOI
• (2024). ASSESSING THE IMPACT OF ASTHMA CONTROL QUESTIONNAIRE SCORE CUTOFFS WITHIN THE MULTICOMPONENT CLINICAL REMISSION ENDPOINT ON CLINICAL OUTCOMES: TRAVERSE OPEN-LABEL STUDY. CHEST. DOI
• (2024). Additive prognostic value of blood eosinophils and exhaled nitric oxide (FeNO) to predict asthma attacks in the ORACLE patient-level meta-analysis. EUROPEAN RESPIRATORY JOURNAL. DOI
• (2024). An Observational and Translational Pilot Study Phenotyping the Response to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA): Interim Results. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2024). An Observational and Translational Pilot Study Phenotyping the Responses to Systemic Corticosteroids in the Management Asthma Attacks (PRISMA): interim translational results. EUROPEAN RESPIRATORY JOURNAL. DOI
• (2024). Biomarkers and phenotyping: a holistic approach to asthma treatment with tezepelumab. EUROPEAN RESPIRATORY JOURNAL. DOI
• Celis-Preciado, C.A., Lachapelle, P., Couillard, S. (2024). Blood eosinophils take centre stage in predicting the response to sublingual immunotherapy (SLIT): A familiar twist. Thorax. DOI
• (2024). Characteristics of long-term oral corticosteroid users stratified by blood eosinophil count in the International Severe Asthma Registry. EUROPEAN RESPIRATORY JOURNAL. DOI
• Gupta, S., Couillard, S., Digby, G., Tse, S.M., Green, S., Penz, E. (2024). Climate Change and Inhaler Selection in Patients With Respiratory Disease. Chest. DOI
• (2024). Legionnaire's Disease Presenting With Combined Neurologic and Cardiac Involvement. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2024). Liberal Withdrawal From Oral Corticosteroids Maintenance Therapy After Introduction of a Biological Agent Targeting Type 2 Inflammation in Severe Asthma. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2024). Multiple Event-time Analysis: A New Approach for Event Based Clinical Trials in Obstructive Airway Diseases. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2024). Multivariable prognostic relations of asthma attack risk factors in the ORACLE patient-level meta-analysis. EUROPEAN RESPIRATORY JOURNAL. DOI
• Bourdin, A., Brusselle, G., Couillard, S., Fajt, M.L., Heaney, L.G., Israel, E., McDowell, P.J., Menzies-Gow, A., Martin, N., Mitchell, P.D., Petousi, N., Quirce, S., Schleich, F., Pavord, I.D. (2024). Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics. Journal of Allergy and Clinical Immunology in Practice. DOI
• (2024). Poutine-induced Hypoxemia: A Case Report. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2024). Predicting Severe Asthma Attacks With Blood Eosinophils and Exhaled Nitric Oxide (FeNO): Initial Data Analysis for the ORACLE Patient-level Meta-analysis. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2024). Prevalence of Asthma Remission in CSAR Cohort. EUROPEAN RESPIRATORY JOURNAL. DOI
• (2024). The Differential Effects of Inhaled and Oral Corticosteroids on Type-2 Inflammation in the Blood and Airway Compartments of Eosinophilic Asthmatics. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• Farmer, M.J.S., Couillard, S., Lastra, A.C., Ramakrishnan, S. (2024). Trailblazing Clinical Trials in Asthma, COPD, Sleep Medicine, and Education and Clinical Practice in 2023. Chest. DOI
• Pelaia, C., Melhorn, J., Hinks, T.S.C., Couillard, S., Vatrella, A., Pelaia, G., Pavord, I.D. (2024). Type 2 severe asthma: pathophysiology and treatment with biologics. Expert Review of Respiratory Medicine. DOI
• (2024). Type-2 biomarker elevation across asthma treatment steps in the ORACLE patient-level meta-analysis of all-comer trials. EUROPEAN RESPIRATORY JOURNAL. DOI
• Simon Couillard, Nayia Petousi, Kate S. Smigiel, Nestor A. Molfino. (2023). Towards a Predict and Prevent Approach in Obstructive Airways Diseases. The Journal of Allergy and Clinical Immunology: In Practice. DOI
• (2023). 'Innumerable' Blast Cells in the Bronchoalveolar Lavage (Pulmonary Leukostasis): A Case Report. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2023). A Rare Case of Congenital Defects in the Newborn of a Patient With Uncontrolled Asthma on Dual Omalizumab-Dupilumab Biological Therapy. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2023). An Unusual Case of Pulmonary Opacities Following Cryoablation. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• Lugogo, N.L., Mohan, A., Akuthota, P., Couillard, S., Rhoads, S., Wechsler, M.E. (2023). Are We Ready for Asthma Remission as a Clinical Outcome?. Chest. DOI
• (2023). Blastomycosis and Multiple Concurrent Pulmonary Infections in a Benralizumab-Treated Asthmatic. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• Gupta, S., Couillard, S., Digby, G., Tse, S.M., Green, S., Aceron, R., Carlsten, C., Hubick, J., Penz, E. (2023). Canadian Thoracic Society Position Statement on Climate Change and Choice of Inhalers for Patients with Respiratory Disease. Canadian Journal of Respiratory Critical Care and Sleep Medicine. DOI
• Couillard, S., Ducharme, F.M., Pavord, I.D. (2023). Clinically accessible biomarkers to assess the modifiable risk of asthma/wheezing attacks in toddlers. Journal of Allergy and Clinical Immunology in Practice. DOI
• Blaiss, M., Oppenheimer, J., Corbett, M., Bacharier, L., Bernstein, J., Carr, T., Chipps, B., Couillard, S., Forno, E., Grant, T., Lugogo, N., May, K., Schauberger, E. (2023). Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Annals of Allergy Asthma and Immunology. DOI
• Celis-Preciado, C.A., Lachapelle, P., Couillard, S. (2023). Exhaled nitric oxide (FeNO): Bridging a knowledge gap in asthma diagnosis and treatment. Clinical and Experimental Allergy. DOI
• (2023). Inhaled and oral corticosteroid treatment highlights differential effects in blood and airway compartments in type-2 high asthma. THORAX. DOI
• Celis-Preciado, C.A., Leclerc, S., Duval, M., Cliche, D.O., Larivée, P., Lemaire-Paquette, S., Lévesque, S., Côté, A., Lachapelle, P., Couillard, S. (2023). Phenotyping the Responses to Systemic Corticosteroids in the Management of Asthma Attacks (PRISMA): protocol for an observational and translational pilot study. BMJ Open Respiratory Research. DOI
• Couillard, S., Côté, A. (2023). Predicting On-Biologic Remission in Asthma: Insight From the Airways. Chest. DOI
• (2023). Relative abundance of Haemophilus as a component of the respiratory microbiome is not associated with airway epithelial MUC5AC staining. EUROPEAN RESPIRATORY JOURNAL. DOI
• Petousi, N., Pavord, I.D., Couillard, S. (2023). The Lancet COPD Commission: broader questions remain. Lancet. DOI
• Petousi, Nayia, Pavord, Ian D., Couillard, Simon. (2023). The Lancet COPD Commission: broader questions remain. The Lancet.
• Simon Couillard. (2022). Le tezepelumab en asthme sévère. Info RQESR.
• (2022). Blood eosinophils, fractional exhaled nitric oxide and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling. BMJ Open. DOI
• Khalfaoui, L., Symon, F.A., Couillard, S., Hargadon, B., Chaudhuri, R., Bicknell, S., Mansur, A.H., Shrimanker, R., Hinks, T.C., Pavord, I.D., Fowler, S.J., Brown, V., McGarvey, L.P., Heaney, L.G., Austin, C.D., Howarth, P.H., Arron, J.R., Choy, D.F., Bradding, P. (2022). Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma. Allergy European Journal of Allergy and Clinical Immunology. DOI
• Crossingham, I., Richardson, R., Hinks, T.S.C., Spencer, S., Couillard, S., Maynard-Paquette, A.-C., Thomassen, D., Howell, I. (2022). BIO-AST Biologics for chronic severe asthma: a network meta-analysis. Cochrane Database of Systematic Reviews. DOI
• Couillard, S., Laugerud, A., Jabeen, M., Ramakrishnan, S., Melhorn, J., Hinks, T., Pavord, I. (2022). Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. Thorax. DOI
• (2022). Development of a Prototype ORACLE Web-app to Predict Treatment Benefits of Type-2 Targeted Anti-Inflammatory Treatment in Asthma. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• Couillard, S., Pavord, I.D. (2022). Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma. Respirology. DOI
• Couillard, S., Shrimanker, R., Lemaire-Paquette, S., Hynes, G.M., Borg, C., Connolly, C., Thulborn, S.J., Moran, A., Poole, S., Morgan, S., Powell, T., Pavord, I., Hinks, T. (2022). Longitudinal changes in sputum and blood inflammatory mediators during FeNO suppression testing. Thorax. DOI
• Couillard, S., Do, W.I.H., Beasley, R., Hinks, T.S.C., Pavord, I.D. (2022). Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype Oxford Asthma Attack Risk Scale (ORACLE). Erj Open Research. DOI
• (2022). Prototype ORACLE Score Validation in NOVELTY: Predicted versus Observed Asthma Exacerbation Rates. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2022). Risk factors for corticosteroid- and antibiotic only-treated asthma attacks in the NOVELTY cohort. EUROPEAN RESPIRATORY JOURNAL. DOI
• Couillard, S., Pavord, I.D., Heaney, L.G., Petousi, N., Hinks, T.S.C. (2022). Sub-stratification of type-2 high airway disease for therapeutic decision-making: A ‘bomb’ (blood eosinophils) meets ‘magnet’ (FeNO) framework. Respirology. DOI
• Olivier St-Germain, Philippe Lachapelle, Ian D Pavord, Simon Couillard, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK. (2022). Tackling ‘People Remodelling’ in Corticosteroid-dependent Asthma with Type-2 Targeting Biologics and a Formal Corticosteroid Weaning Protocol. US Respiratory & Pulmonary Diseases. DOI
• Couillard, S. (2022). The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence. European Respiratory Journal. DOI
• (2021). Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. BMJ Open Respiratory Research. DOI
• (2021). The controversial role of as-needed short-acting β2-agonist monotherapy in mild asthma: Short review of current guidelines. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. DOI
• (2021). How I do it. Work-up of severe asthma. Chest. DOI
• Ramakrishnan, S., Couillard, S. (2021). Antibiotics for asthma attacks: Masking uncertainty. European Respiratory Journal. DOI
• Couillard, S., Connolly, C., Borg, C., Pavord, I. (2021). Asthma in pregnancy: An update. Obstetric Medicine. DOI
• (2021). CORRELATION OF EOTAXIN-3 GENE EXPRESSION AND OTHER IL-13-INDUCED GENES IN PATIENTS WITH ASTHMA. THORAX. DOI
• (2021). FENO NON-SUPPRESSION IDENTIFIES CORTICOSTEROID-RESISTANT TYPE-2 SIGNALING IN SEVERE ASTHMA. THORAX. DOI
• Couillard, S., Shrimanker, R., Chaudhuri, R., Mansur, A.H., McGarvey, L.P., Heaney, L.G., Fowler, S.J., Bradding, P., Pavord, I.D., Hinks, T.S.C. (2021). Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma. American Journal of Respiratory and Critical Care Medicine. DOI
• (2021). Raised FeNO in optimally-treated severe asthma identifies persistent eosinophilic chemotactic pull towards the airway. EUROPEAN RESPIRATORY JOURNAL. DOI
• (2021). TO WHAT EXTENT DOES THE PROTOTYPE ORACLE SCALE PREDICT TREATMENT BENEFITS? PREDICTED VERSUS OBSERVED IMPACT OF ANTI-INFLAMMATORY TREATMENTS. THORAX. DOI
• (2021). UTILITY OF ADHERENCE CHECKS IN PATIENTS WITH SEVERE ASTHMA ELIGIBLE FOR BIOLOGICS: A SINGLE CENTRE RETROSPECTIVE ANALYSIS. THORAX. DOI
• (2020). Reply to: Don't Forget About Facilitatory Effects of Corticosteroids on beta-2 adrenoceptors in Acute Asthma. American journal of respiratory and critical care medicine. DOI
• (2020). Healthcare utilization after a first hospitalization for COPD: a new approach of State Sequence Analysis based on the '6W' multidimensional model of care trajectories. BMC health services research. DOI
• (2020). A Case of Follicular Lymphoma Presenting as Severe Interstitial Pneumonia. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• Moran, A.M., Ramakrishnan, S., Borg, C.A., Connolly, C.M., Couillard, S., Mwasuku, C.M., Pavord, I.D., Hinks, T.S.C., Lehtimäki, L. (2020). Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma. American Journal of Respiratory and Critical Care Medicine. DOI
• (2020). Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma. EUROPEAN RESPIRATORY JOURNAL. DOI
• (2020). Mechanisms of FeNO Non-Suppression in Severe Asthma: Analysis of Sputum Type 2 Cytokines and Chemokines. European Respiratory Journal. DOI
• (2019). Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths. International journal of chronic obstructive pulmonary disease. DOI
• (2019). Leon Gerin, becoming a sociologist in a world in transition. RECHERCHES SOCIOGRAPHIQUES.
• Couillard, S., Bélanger, M., Bouchard, N. (2019). Q fever presenting as miliary pneumonia: Case imagery and differential diagnosis. Canadian Journal of Respiratory Critical Care and Sleep Medicine. DOI
• (2018). Eosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec, Canada. International journal of chronic obstructive pulmonary disease. DOI
• (2018). Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. International journal of chronic obstructive pulmonary disease. DOI
• (2018). Blood Eosinophil Levels in First Hospitalization for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) Are Associated with Increased COPD-Related Readmissions. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2018). Miliary Pneumonia as a Novel Radiological Manifestation of Q Fever. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE.
• (2017). Predicting One-year Mortality After a "First" Hospitalization for Chronic Obstructive Pulmonary Disease: An Eight-Variable Assessment Score Tool. COPD. DOI
• (2016). Eosinophils in COPD Exacerbations Are Associated With Increased Readmissions. Chest. DOI
• (2014). Perception of bronchoconstriction following methacholine and eucapnic voluntary hyperpnea challenges in elite athletes. Chest. DOI

Chapitres de livre

• (2021). Biological Therapies for Asthma. Encyclopedia of Respiratory Medicine 2nd Edition. DOI

Autres contributions

Affiches pour une conférence

• (2021). A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE). American Thoracic Society. DOI

Activités professionnelles

• American College of Chest Physicians. Chest Journal. Assistant-editor (asthma). Glenview, Illinois, États-Unis. (2023-).
• Canadian Thoracic Society. CJRCCSM Journal. Junior-editor (asthma). Ottawa, ON, Canada. (2023-2024).
• American College of Chest Physicians. Chest Journal. Early Career Editorial Board Member - Asthma. Glenview, IL, États-Unis. (2022-2023).